152 related articles for article (PubMed ID: 21946231)
21. Oncogenic PTEN functions and models in T-cell malignancies.
Tesio M; Trinquand A; Macintyre E; Asnafi V
Oncogene; 2016 Jul; 35(30):3887-96. PubMed ID: 26616857
[TBL] [Abstract][Full Text] [Related]
22. EZH2 Methyltransferase Activity Controls Pten Expression and mTOR Signaling during Fear Memory Reconsolidation.
Jarome TJ; Perez GA; Hauser RM; Hatch KM; Lubin FD
J Neurosci; 2018 Aug; 38(35):7635-7648. PubMed ID: 30030400
[TBL] [Abstract][Full Text] [Related]
23. Role of mTOR signaling pathway proteins and proteins influencing mTOR pathway in resistance to radiotherapy in prostate cancer.
Benderli Cihan Y
J BUON; 2018; 23(6):1931-1932. PubMed ID: 30610829
[No Abstract] [Full Text] [Related]
24. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo.
Hambardzumyan D; Becher OJ; Rosenblum MK; Pandolfi PP; Manova-Todorova K; Holland EC
Genes Dev; 2008 Feb; 22(4):436-48. PubMed ID: 18281460
[TBL] [Abstract][Full Text] [Related]
25. Loss of PTEN is associated with progression to androgen independence.
Bertram J; Peacock JW; Fazli L; Mui AL; Chung SW; Cox ME; Monia B; Gleave ME; Ong CJ
Prostate; 2006 Jun; 66(9):895-902. PubMed ID: 16496415
[TBL] [Abstract][Full Text] [Related]
26. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
Braglia L; Zavatti M; Vinceti M; Martelli AM; Marmiroli S
Biochim Biophys Acta Mol Cell Res; 2020 Sep; 1867(9):118731. PubMed ID: 32360668
[TBL] [Abstract][Full Text] [Related]
27. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
28. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer.
Wu C; Huang J
J Biol Chem; 2007 Feb; 282(6):3571-83. PubMed ID: 17148458
[TBL] [Abstract][Full Text] [Related]
29. Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells.
Lee SO; Lou W; Nadiminty N; Lin X; Gao AC
Prostate; 2005 Jul; 64(2):160-7. PubMed ID: 15678501
[TBL] [Abstract][Full Text] [Related]
30. MiR-21 modulates radiosensitivity of cervical cancer through inhibiting autophagy via the PTEN/Akt/HIF-1α feedback loop and the Akt-mTOR signaling pathway.
Song L; Liu S; Zhang L; Yao H; Gao F; Xu D; Li Q
Tumour Biol; 2016 Sep; 37(9):12161-12168. PubMed ID: 27220494
[TBL] [Abstract][Full Text] [Related]
31. Predictive value of EGFR-PI3K-pAKT-mTOR-pS6 pathway in sinonasal squamous cell carcinomas.
Muñoz-Cordero MG; López F; García-Inclán C; López-Hernández A; Potes-Ares S; Fernández-Vañes L; Llorente JL; Hermsen M
Acta Otorrinolaringol Esp (Engl Ed); 2019; 70(1):16-24. PubMed ID: 29573781
[TBL] [Abstract][Full Text] [Related]
32. The role and therapeutic implications of PI3K signaling pathway in cancer.
Leiphrakpam PD; Chowdhury S; Wang J; Black JD; Are C
J Surg Oncol; 2021 Jan; 123(1):39-41. PubMed ID: 33179260
[No Abstract] [Full Text] [Related]
33. Genetic modelling of the PTEN/AKT pathway in cancer research.
Renner O; Blanco-Aparicio C; Carnero A
Clin Transl Oncol; 2008 Oct; 10(10):618-27. PubMed ID: 18940742
[TBL] [Abstract][Full Text] [Related]
34. INPP4B: the new kid on the PI3K block.
Agoulnik IU; Hodgson MC; Bowden WA; Ittmann MM
Oncotarget; 2011 Apr; 2(4):321-8. PubMed ID: 21487159
[TBL] [Abstract][Full Text] [Related]
35. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
Petrella BL; Brinckerhoff CE
Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
[TBL] [Abstract][Full Text] [Related]
36. Targeting the PI3K/AKT pathway for the treatment of prostate cancer.
Sarker D; Reid AH; Yap TA; de Bono JS
Clin Cancer Res; 2009 Aug; 15(15):4799-805. PubMed ID: 19638457
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer heterogeneity: Discovering novel molecular targets for therapy.
Ciccarese C; Massari F; Iacovelli R; Fiorentino M; Montironi R; Di Nunno V; Giunchi F; Brunelli M; Tortora G
Cancer Treat Rev; 2017 Mar; 54():68-73. PubMed ID: 28231559
[TBL] [Abstract][Full Text] [Related]
38. Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model.
Wang Z; Xu D; Ding HF; Kim J; Zhang J; Hai T; Yan C
Oncogene; 2015 Sep; 34(38):4975-84. PubMed ID: 25531328
[TBL] [Abstract][Full Text] [Related]
39. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
[TBL] [Abstract][Full Text] [Related]
40. Alcohol Dehydrogenase Protects against Endoplasmic Reticulum Stress-Induced Myocardial Contractile Dysfunction via Attenuation of Oxidative Stress and Autophagy: Role of PTEN-Akt-mTOR Signaling.
Pang J; Fuller ND; Hu N; Barton LA; Henion JM; Guo R; Chen Y; Ren J
PLoS One; 2016; 11(1):e0147322. PubMed ID: 26807981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
